ArticleOncotarget2022

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.

Yehia I Mohamed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.